Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
BeOne Medicines
ViroMissile, Inc.
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Eli Lilly and Company
Eli Lilly and Company
Oscotec Inc.
Innate Pharma
NeoTX Therapeutics Ltd.
Hangzhou DAC Biotechnology Co., Ltd.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
NextPoint Therapeutics, Inc.
Columbia University
Theratechnologies
Oxford Vacmedix UK Ltd.
Agenus Inc.
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Astellas Pharma Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Pfizer
Prelude Therapeutics
Lebanese University
Canadian Cancer Trials Group
AvenCell Therapeutics, Inc.
Xencor, Inc.
Mirati Therapeutics Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Imperial College London
NRG Oncology
MacroGenics
MacroGenics
MacroGenics
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Celgene
MedImmune LLC
AbbVie
Pfizer
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota